Symbols

ARVN

Arvinas·NASDAQ

--(--)

ARVN fundamentals

ARVN Q4 2025 Earnings

Arvinas (ARVN) released its earnings on Feb 24, 2026: revenue was 9.50M (YoY -83.95%), missed estimates; EPS was -1.1 (YoY -74.60%), missed estimates.

Revenue / YoY

9.50M

-83.95%

EPS / YoY

-1.1

-74.60%

Report date

Feb 24, 2026

ARVN Earnings Call Summary for Q4,2025

Pipeline differentiation: 4 Phase I programs (ARV-102, ARV-806, ARV-393, ARV-027) targeting unmet needs in neurology and oncology.
2026 data catalysts: ARV-102 Parkinson's biomarker data (AD/PD 2026), ARV-806 KRAS G12D clinical data (mid-2026), ARV-393 lymphoma efficacy updates.
Financial stability: $685M cash balance with runway to H2 2028; 43% YoY G&A reduction.
Partnership focus: Vepdegestrant commercialization discussions; potential registrational trial for ARV-102 in PSP by end-2026.

Earnings

EPS

Revenue

Revenue & Expenses

ARVN has released its 2025 Q4 earnings report, with revenue of 9.50M, reflecting a YoY change of -83.95%, and net profit of -67.40M, showing a YoY change of -49.45%. The Sankey diagram below clearly presents ARVN's revenue sources and cost distribution.

Key Indicators

Arvinas (ARVN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Arvinas (ARVN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Arvinas (ARVN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Arvinas (ARVN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown